FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4210362744> ?p ?o ?g. }

• W4210362744 endingPage "e003091" @default.
• W4210362744 startingPage "e003091" @default.
• W4210362744 abstract "Several studies have evaluated the relationship between tumor mutational burden (TMB) and outcomes of immune checkpoint inhibitors. In the phase II KEYNOTE-158 study of pembrolizumab monotherapy for previously treated recurrent or metastatic cancer, high TMB as assessed by the FoundationOne CDx was associated with an improved objective response rate (ORR).We retrospectively assessed the relationship between TMB and efficacy in participants with previously treated advanced solid tumors enrolled in 12 trials that evaluated pembrolizumab monotherapy, including 3 randomized trials that compared pembrolizumab with chemotherapy. TMB was assessed in formalin-fixed, paraffin-embedded pretreatment tumor samples by whole-exome sequencing. High TMB was defined as ≥175 mutations/exome. Microsatellite instability (MSI) phenotype was based on whole-exome sequencing results. Programmed death ligand 1 (PD-L1) expression was assessed by immunohistochemistry. The primary end point was ORR assessed per RECIST V.1.1 by independent central review. Other end points included progression-free survival (PFS) assessed per RECIST V.1.1 by independent central review and overall survival (OS).Of the 2234 participants in the analysis, 1772 received pembrolizumab monotherapy and 462 received chemotherapy. Among the pembrolizumab-treated participants, ORR was 31.4% (95% CI 27.1 to 36.0) in the 433 participants with TMB ≥175 mutations/exome and 9.5% (95% CI 8.0 to 11.2) in the 1339 participants with TMB <175 mutations/exome. The association of TMB with ORR was observed regardless of PD-L1 expression and not driven by specific tumor types or participants with very high TMB or high MSI. In the 3 randomized controlled trials, TMB was associated with ORR (p≤0.016), PFS (p≤0.005), and OS (p≤0.029) of pembrolizumab but not of chemotherapy (p≥0.340, p≥0.643, and p≥0.174, respectively), and pembrolizumab improved efficacy versus chemotherapy in participants with TMB ≥175 mutations/exome.TMB ≥175 mutations/exome is associated with clinically meaningful improvement in the efficacy of pembrolizumab monotherapy and improved outcomes for pembrolizumab versus chemotherapy across a wide range of previously treated advanced solid tumor types. These data suggest TMB has broad clinical utility irrespective of tumor type, PD-L1 expression, or MSI status and support its use as a predictive biomarker for pembrolizumab monotherapy in participants with previously treated advanced solid tumors." @default.
• W4210362744 created "2022-02-08" @default.
• W4210362744 creator A5009613920 @default.
• W4210362744 creator A5017085262 @default.
• W4210362744 creator A5029073714 @default.
• W4210362744 creator A5053254472 @default.
• W4210362744 creator A5060841115 @default.
• W4210362744 creator A5061867713 @default.
• W4210362744 creator A5065172378 @default.
• W4210362744 creator A5071080700 @default.
• W4210362744 creator A5074861706 @default.
• W4210362744 creator A5076360051 @default.
• W4210362744 creator A5077921482 @default.
• W4210362744 date "2022-01-01" @default.
• W4210362744 modified "2023-10-15" @default.
• W4210362744 title "Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors" @default.
• W4210362744 cites W1809627231 @default.
• W4210362744 cites W1982488143 @default.
• W4210362744 cites W2011458181 @default.
• W4210362744 cites W2049553585 @default.
• W4210362744 cites W2152061559 @default.
• W4210362744 cites W2198093519 @default.
• W4210362744 cites W2338494814 @default.
• W4210362744 cites W2345415641 @default.
• W4210362744 cites W2347070489 @default.
• W4210362744 cites W2560367415 @default.
• W4210362744 cites W2568054806 @default.
• W4210362744 cites W2570159314 @default.
• W4210362744 cites W2572174216 @default.
• W4210362744 cites W2588916311 @default.
• W4210362744 cites W2602907503 @default.
• W4210362744 cites W2606495925 @default.
• W4210362744 cites W2655262992 @default.
• W4210362744 cites W2747774814 @default.
• W4210362744 cites W2775505643 @default.
• W4210362744 cites W2779221466 @default.
• W4210362744 cites W2793364080 @default.
• W4210362744 cites W2797675588 @default.
• W4210362744 cites W2806614796 @default.
• W4210362744 cites W2811088815 @default.
• W4210362744 cites W2890261294 @default.
• W4210362744 cites W2892310829 @default.
• W4210362744 cites W2897815318 @default.
• W4210362744 cites W2902530914 @default.
• W4210362744 cites W2904444972 @default.
• W4210362744 cites W2909679049 @default.
• W4210362744 cites W2913529349 @default.
• W4210362744 cites W2914458127 @default.
• W4210362744 cites W2944817662 @default.
• W4210362744 cites W2964160738 @default.
• W4210362744 cites W2972600793 @default.
• W4210362744 cites W2987711192 @default.
• W4210362744 cites W2990771207 @default.
• W4210362744 cites W3037355837 @default.
• W4210362744 cites W3080192585 @default.
• W4210362744 cites W3083986479 @default.
• W4210362744 cites W3131681136 @default.
• W4210362744 cites W3136653115 @default.
• W4210362744 cites W3138258440 @default.
• W4210362744 cites W3155701853 @default.
• W4210362744 doi "https://doi.org/10.1136/jitc-2021-003091" @default.
• W4210362744 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35101941" @default.
• W4210362744 hasPublicationYear "2022" @default.
• W4210362744 type Work @default.
• W4210362744 citedByCount "49" @default.
• W4210362744 countsByYear W42103627442022 @default.
• W4210362744 countsByYear W42103627442023 @default.
• W4210362744 crossrefType "journal-article" @default.
• W4210362744 hasAuthorship W4210362744A5009613920 @default.
• W4210362744 hasAuthorship W4210362744A5017085262 @default.
• W4210362744 hasAuthorship W4210362744A5029073714 @default.
• W4210362744 hasAuthorship W4210362744A5053254472 @default.
• W4210362744 hasAuthorship W4210362744A5060841115 @default.
• W4210362744 hasAuthorship W4210362744A5061867713 @default.
• W4210362744 hasAuthorship W4210362744A5065172378 @default.
• W4210362744 hasAuthorship W4210362744A5071080700 @default.
• W4210362744 hasAuthorship W4210362744A5074861706 @default.
• W4210362744 hasAuthorship W4210362744A5076360051 @default.
• W4210362744 hasAuthorship W4210362744A5077921482 @default.
• W4210362744 hasBestOaLocation W42103627441 @default.
• W4210362744 hasConcept C104317684 @default.
• W4210362744 hasConcept C10590036 @default.
• W4210362744 hasConcept C121608353 @default.
• W4210362744 hasConcept C126322002 @default.
• W4210362744 hasConcept C143998085 @default.
• W4210362744 hasConcept C16671776 @default.
• W4210362744 hasConcept C180754005 @default.
• W4210362744 hasConcept C203092338 @default.
• W4210362744 hasConcept C2777701055 @default.
• W4210362744 hasConcept C2779767149 @default.
• W4210362744 hasConcept C2779984678 @default.
• W4210362744 hasConcept C2780057760 @default.
• W4210362744 hasConcept C31760486 @default.
• W4210362744 hasConcept C501734568 @default.
• W4210362744 hasConcept C535046627 @default.
• W4210362744 hasConcept C54355233 @default.
• W4210362744 hasConcept C61320498 @default.
• W4210362744 hasConcept C71924100 @default.

• next